Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy

作     者：Jian Xue Hongbo Ni Fan Wang Ke Xu Meng Niu Jian Xue;Hongbo Ni;Fan Wang;Ke Xu;Meng Niu

作者机构：Department of Interventional RadiologyThe First Affiliated Hospital of China Medical UniversityShenyangLiaoning110000China 

出 版 物：《Journal of Interventional Medicine》 (介入医学杂志（英文）)

年 卷 期：2021年第4卷第3期

页      面：105-113页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by National Key Research and Development Program of China Grant under No.2019YFC0118100。 

主　　题：Hepatocellular carcinoma Locoregional therapy Immunotherapy Targeted therapy Combination therapy 

摘      要：Locoregional therapies(LRTs)of hepatocellular carcinoma(HCC)represented by ablation and TACE has become the main means for the clinical treatment of unresectable HCC.Among these,TACE is used throughout the stageⅠb toⅢb of HCC treatment.In recent years,immunotherapy led by immune checkpoint inhibitors has become a hot direction in clinical research.At the same time,targeted drugs such as Sorafenib and Apatinib have played an important role in the treatment and complementary therapy of advanced HCC,and their clinical application has been quite mature.HCC is the sixth most common malignant tumor in the world.When it comes to its treatment,different therapies have different indications,and their individual efficacies are not satisfactory,which makes the exploration of the use of combination therapy in HCC treatment become a new trend.In this paper,the status of the three therapies and the progress of their combined application are briefly reviewed.